A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs RG 7880 (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions
- Sponsors Genentech
- 26 Jul 2017 Planned End Date changed from 1 Nov 2017 to 21 May 2018.
- 26 Jul 2017 Planned primary completion date changed from 1 Nov 2017 to 21 May 2018.
- 20 Jul 2016 New trial record